| Stage | VVV | % of rev | MLAB | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $545M | 100.00% | $60M | 100.00% | VVV ×9.06 |
| Gross profit | $215M | 39.46% | $39M | 64.87% | MLAB +25.4pp |
| Operating income | $112M | 20.60% | $7M | 11.69% | VVV +8.9pp |
| Pre-tax income | $86M | 15.72% | $4M | 7.24% | VVV +8.5pp |
| Net income | $65M | 11.84% | $3M | 4.71% | VVV +7.1pp |
| Stage | VVV | MLAB | Gap · A − B |
|---|---|---|---|
| Revenue | $545M100.00% | $60M100.00% | VVV ×9.06 |
| Gross profit | 39.46%$215M | 64.87%$39M | MLAB +25.4pp |
| Operating income | 20.60%$112M | 11.69%$7M | VVV +8.9pp |
| Pre-tax income | 15.72%$86M | 7.24%$4M | VVV +8.5pp |
| Net income |
| 11.84%$65M |
| 4.71%$3M |
| VVV +7.1pp |
No disclosed counterparties: MLAB.
None